Építés alatt – nem éles oldal
Belépés
Befejeződött1. fázis

A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

A legfontosabb adatok

Ki végzi
GlaxoSmithKline
Hol
Belgium, Kanada és Spanyolország5 helyszín, 3 országbanVálassz országot a helyszínekhez
Állapot
Befejeződött
Fázis
1. fázis
Résztvevők
324 fő vett részt
Kezdés
2022. aug. 9.
Befejezés
2024. márc. 26.
A vizsgálat típusa
Beavatkozással járó, 13 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • GSK4382276A Dose level 1
  • GSK4382276A Dose level 2
  • GSK4382276A Dose level 3
  • GSK4382276A Dose level 4
  • GSK4382276A Dose level 5
  • GSK4382276A Dose level 6
  • GSK4382276A Dose level 7
  • GSK4382276A Dose level 8
  • GSK4382276A Dose level 9
  • GSK4382276A Dose level 10
  • FDQ21A-NH
  • FDQ22A-NH
A regiszteradat frissítve
2026. március 10.

Ki vehet részt

Életkor
18 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 30 feltétel megnézéseKevesebb

Ki vehet részt

  • A male or female between and including 18 and 45 years of age (YAs) or between and including 60 and 80 years of age (OAs) at the time of the study intervention administration. The age of sentinel participants in OA category will be limited to maximum 70 years
  • Healthy or medically stable participants as established by medical history, safety laboratory assessments and clinical examination
  • Body mass index >= 18 kg/m\^2 and <= 32 kg/m\^2
  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol
  • Written informed consent obtained from the participant prior to performing any study-specific procedure
  • Female participants of non-childbearing potential may be enrolled in the study
  • Female participants of childbearing potential may be enrolled in the study if the participant:; has practiced adequate contraception for 28 days prior to study intervention administration, and; has a negative pregnancy test on the day of study intervention administration, and; has agreed to continue adequate contraception for at least 1 month after study intervention administration

Ki nem vehet részt

  • Administration of seasonal influenza vaccine within 180 days before enrollment or planned administration up to Visit 4 (Day 29)
  • Administration of a vaccine not foreseen by the study protocol in the period starting 28 days before the study intervention administration, or planned administration within 28 days after the study intervention administration*, with the exception of vaccines authorized or approved for the prevention of COVID-19 (regardless of the type of vaccine); *In case emergency mass vaccination for an unforeseen public health threat is organized by public health authorities outside the routine immunization program, the time period described above can be reduced to 7 days, if necessary, for that mass vaccination vaccine, provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly
  • Use of any investigational or non-registered product (drug, vaccine or invasive medical device) other than the study intervention during the period beginning 30 days before the study intervention administration, or their planned use during the study period
  • Administration of long-acting immune-modifying drugs within 90 days before enrollment or planned use at any time during the study period
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the study intervention administration, or planned administration during the study period. Administration of monoclonal antibodies specifically directed against the spike protein of SARS-CoV-2 virus, for treatment of COVID-19 disease is allowed
  • Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the study intervention administration. For corticosteroids, this will mean prednisone equivalent ≥ 20 mg/day. Inhaled, topical and intraarticular steroids are allowed
  • Previous enrolment in this study; Other exclusions
  • Previous enrollment in this study
  • Medical conditions
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention (including latex, poly-ethylene-glycol, egg protein and aminoglycoside antibiotics)
  • Recurrent history or uncontrolled neurological disorders or seizures, including Guillain-Barré syndrome and Bell's palsy, with the exception of febrile seizures during childhood
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study
  • History of abusive alcohol and/or drug consumption in the past 5 years
  • Any clinically significant hematological coagulation or urine analysis laboratory abnormality; The investigator should use his/her clinical judgement to decide which abnormalities are clinically significant
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection, based on medical history and physical examination (no laboratory testing required)
  • Significant exposure to persons with influenza or laboratory-confirmed SARS-CoV-2 within 7 days prior to Visit 1 (Day 1) and for whom a SARS-CoV-2 PCR test has not (yet) been confirmed as negative; Prior/Concomitant therapy
  • Current or past malignancy, unless completely resolved without sequelae for >5 years
  • Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or review of the participant's medical record
  • Pregnant or lactating female
  • Female planning to become pregnant or planning to discontinue contraceptive precautions within the 1-month post-dosing period
  • Any study personnel or their immediate dependents, family, or household members
  • Participants with extensive tattoos covering deltoid region on both arms that would preclude the assessment of local reactogenicity

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

3 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this first-time-in-human (FTiH) study is to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based monovalent vaccine (GSK4382276A) candidate against influenza in healthy younger adults (YA) and older adults (OA).

A vizsgálat 13 csoportja

  • Flu mRNA_Dose level 1_Younger adults (YA)A vizsgált kezelés

    On Day 1, YA adult participants received Flu mRNA at Dose Level 1, the lowest concentration evaluated in the study.

    Kezelés: GSK4382276A Dose level 1

  • Flu mRNA_Dose level 2 _YAA vizsgált kezelés

    On Day 1, YA participants received Flu mRNA at Dose Level 2, which corresponds to a higher concentration than Dose Level 1.

    Kezelés: GSK4382276A Dose level 2

  • Flu mRNA_Dose level 3_YAA vizsgált kezelés

    On Day 1, YA participants received Flu mRNA at Dose Level 3, which corresponds to a higher concentration than Dose Level 2.

    Kezelés: GSK4382276A Dose level 3

  • Flu mRNA_Dose level 4_YAA vizsgált kezelés

    On Day 1, YA participants received Flu mRNA at Dose Level 4, which corresponds to a higher concentration than Dose Level 3.

    Kezelés: GSK4382276A Dose level 4

  • Flu mRNA_Dose level 5_YAA vizsgált kezelés

    On Day 1, YA participants received Flu mRNA at Dose Level 5, which corresponds to a higher concentration than Dose Level 4.

    Kezelés: GSK4382276A Dose level 5

  • Flu mRNA_Dose level 6_YAA vizsgált kezelés

    On Day 1, YA participants received Flu mRNA at Dose Level 6, which corresponds to a higher concentration than Dose Level 5.

    Kezelés: GSK4382276A Dose level 6

  • Flu mRNA_Dose level 7_YAA vizsgált kezelés

    On Day 1, YA participants received Flu mRNA at Dose Level 7, which corresponds to a higher concentration than Dose Level 6.

    Kezelés: GSK4382276A Dose level 7

  • Flu mRNA_ Dose level 8_YAA vizsgált kezelés

    On Day 1, YA participants received Flu mRNA at Dose Level 8, which corresponds to a higher concentration than Dose Level 7.

    Kezelés: GSK4382276A Dose level 8

  • Flu mRNA_Dose level 9_YAA vizsgált kezelés

    On Day 1, YA participants received Flu mRNA at Dose Level 9, which corresponds to a higher concentration than Dose Level 8.

    Kezelés: GSK4382276A Dose level 9

  • Flu mRNA_Dose level 10_YAA vizsgált kezelés

    On Day 1, YA participants received Flu mRNA at Dose Level 10, the highest concentration evaluated in the study.

    Kezelés: GSK4382276A Dose level 10

  • Pooled Control_YAMár használt kezelés, összehasonlításként

    On Day 1, YA participants received a single dose of FDQ21A - NH or FDQ22A -NH administered as a control and were analyzed together as pooled group throughout the study.

    Kezelés: FDQ21A-NH és FDQ22A-NH

  • Flu mRNA_Dose level 7_Older adults (OA)A vizsgált kezelés

    On Day 1, OA participants received Flu mRNA at Dose Level 7.

    Kezelés: GSK4382276A Dose level 7

  • Control_OAMár használt kezelés, összehasonlításként

    On Day 1, OA participants received a single dose of FDQ21A-NH administered at as a control.

    Kezelés: FDQ21A-NH

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 1 Randomized, Dose Escalation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of an mRNA-based Monovalent Influenza Vaccine Candidate in Healthy Younger and Older Adults
Publikációk
A regiszteradat frissítve
2026. március 10.